Autor(es):
Kislaya, Irina ; Sentís, Alexis ; Starrfelt, Jostein ; Nunes, Baltazar ; Martínez‐Baz, Iván ; Nielsen, Katrine Finderup ; AlKerwi, Ala'a ; Braeye, Toon ; Fontán‐Vela, Mario ; Bacci, Sabrina ; Meijerink, Hinta ; Castilla, Jesús ; Emborg, Hanne‐Dorthe ; Hansen, Christian Holm ; Schmitz, Susanne ; Van Evercooren, Izaak ; Valenciano, Marta ; Nardone, Anthony ; Nicolay, Nathalie ; Monge, Susana ; VEBIS‐Lot4 working group
Data: 2023
Identificador Persistente: http://hdl.handle.net/10400.18/9105
Origem: Repositório Científico do Instituto Nacional de Saúde
Assunto(s): COVID-19; SARS-CoV-2; COVID-19-Related Death; Cohort Design; Hospitalization; Vaccine Effectiveness; Vacina; Efetividade; VEBIS- LOTE 4; Cuidados de Saúde
Descrição
Background: Within the ECDC-VEBIS project, we prospectively monitored vaccine effectiveness (VE) against COVID-19 hospitalisation and COVID-19-related death using electronic health registries (EHR), between October 2021 and November 2022, in community-dwelling residents aged 65-79 and ≥80 years in six European countries. Methods: EHR linkage was used to construct population cohorts in Belgium, Denmark, Luxembourg, Navarre (Spain), Norway and Portugal. Using a common protocol, for each outcome, VE was estimated monthly over 8-week follow-up periods, allowing 1 month-lag for data consolidation. Cox proportional-hazards models were used to estimate adjusted hazard ratios (aHR) and VE = (1 - aHR) × 100%. Site-specific estimates were pooled using random-effects meta-analysis. Results: For ≥80 years, considering unvaccinated as the reference, VE against COVID-19 hospitalisation decreased from 66.9% (95% CI: 60.1; 72.6) to 36.1% (95% CI: -27.3; 67.9) for the primary vaccination and from 95.6% (95% CI: 88.0; 98.4) to 67.7% (95% CI: 45.9; 80.8) for the first booster. Similar trends were observed for 65-79 years. The second booster VE against hospitalisation ranged between 82.0% (95% CI: 75.9; 87.0) and 83.9% (95% CI: 77.7; 88.4) for the ≥80 years and between 39.3% (95% CI: -3.9; 64.5) and 80.6% (95% CI: 67.2; 88.5) for 65-79 years. The first booster VE against COVID-19-related death declined over time for both age groups, while the second booster VE against death remained above 80% for the ≥80 years. Conclusions: Successive vaccine boosters played a relevant role in maintaining protection against COVID-19 hospitalisation and death, in the context of decreasing VE over time. Multicountry data from EHR facilitate robust near-real-time VE monitoring in the EU/EEA and support public health decision-making.
